Showing results (171-180 of 231) with videos related to
Sort By:
Pageof 24
Plos Clinical Trials|July 28, 2006
A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard StudyMike Youle, Sean Emery, Martin Fisher, et al.AIDS (London, England)|December 13, 2001
Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapyGillian L Dean, Simon G Edwards, Natalie J Ives, et al.AIDS (London, England)|March 28, 2014
Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participantsFrank J Palella, Martin Fisher, Pablo Tebas, et al.The Journal of Infectious Diseases|July 29, 2009
Virological response to initial antiretroviral regimens containing abacavir or tenofovirLoveleen Bansi, Caroline Sabin, Richard Gilson, et al.Antimicrobial Agents and Chemotherapy|May 11, 2016
Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous MeningitisSam Nightingale, Tran Thi Hong Chau, Martin Fisher, et al.Journal of the International AIDS Society|November 14, 2014
Sexual behaviour, recreational drug use and hepatitis C co-infection in HIV-diagnosed men who have sex with men in the United Kingdom: results from the ASTRA studyMarina Daskalopoulou, Alison Rodger, Alicia Thornton, et al.The Journal of Infectious Diseases|March 4, 2014
Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposureSophie Jose, Lisa Hamzah, Lucy J Campbell, et al.Journal of Clinical Epidemiology|March 30, 2010
Data linkage reduces loss to follow-up in an observational HIV cohort studyTeresa Hill, Loveleen Bansi, Caroline Sabin, et al.Lancet (London, England)|December 11, 2007
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort studyAndrew N Phillips, Clifford Leen, Alan Wilson, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|June 26, 2009
Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort studyLoveleen Bansi, Jo Turner, Richard Gilson, et al.Pageof 24